VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type ...(ssociated with the disease said Leland ...),Health

Date:6/8/2009

ssociated with the disease," said Leland Wilson, president and chief executive officer of VIVUS. "The study results we have seen thus far across the clinical development program for Qnexa reinforce Qnexa's potential in the treatment of type 2 diabetes, and, importantly, in treating co-morbidities including high blood pressure. During last year's ADA meeting, we showed that type 2 diabetics were able to lower their blood sugar and lose weight after six months of treatment with Qnexa. The DM-230 study confirms our original findings and shows continued improvement in blood sugar and sustained weight loss for one year in this difficult-to-treat population."

"Qnexa has shown very promising data to date as a potential therapy to treat obesity in type 2 diabetic patients. This is exciting as it addresses one of the main etiologies of type 2 diabetes -- the weight. This study in a real-world population of type 2 diabetics, applied on a background of rigorous standard of care treatment, shows the true potential of Qnexa in this population," stated Barbara Troupin, M.D., MBA, Clinical Leader for Qnexa Diabetes.

About the DM-230 Study

The DM-230 study was a 56-week, randomized, double-blind, placebo-controlled, efficacy and safety study assessing the impact of Qnexa on glycemic management in 130 obese (90 females, 40 males with an average age of 50 years) type 2 diabetics at 10 study sites. A majority of the patients had been diagnosed with diabetes for more the five years and were taking two or more oral diabetes medications. Subjects in the study were actively managed according to American Diabetes Association (ADA) standards of care with respect to diabetes medications and lifestyle. Patients receiving placebo required significant increases in the number and doses of concurrent anti-diabetic medications to comply with study required glycemic thresholds. Thus, the observed reduction in HbA1c in the placebo trea
'/>"/>

SOURCE VIVUS, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. New Diabetes Drug Shows Promise in Trial
2. Vaporized viral vector shows promise in anti-cancer gene therapy
3. New Survey Shows Americans Strongly Support Guaranteed Dental Coverage in Healthcare Reform
4. Global Testing Shows No Variation in Swine Flu Virus
5. New Study Shows Many U.S. Contact Lens Wearers Do Not Comply With Recommended Replacement Schedules
6. Protein may be strongest indicator of rare lung disease, study shows
7. People who wear rose-colored glasses see more, University of Toronto study shows
8. Computer modeling shows strategies to rein in epidemics need to be retooled for rural populations
9. New study shows people with mental health problems receive inadequate medical care
10. The Killing of George Tiller: Video "Thine Eyes" Shows True Face of Pro-life Movement in the Face of 'Terrorist' Accusations
11. New Market Research Study Shows Lung Cancer Treatments Differ Significantly by Both Age and Geography